Citanest forte, Fortacin(prilocaine)
Citanest, Fortacin, Oraqix (prilocaine) is a small molecule pharmaceutical. Prilocaine was first approved as Citanest forte on 1982-01-01. It is used to treat pain in the USA. It has been approved in Europe to treat physiological sexual dysfunction and premature ejaculation.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
urogenital diseases | D000091642 |
signs and symptoms pathological conditions | D013568 |
psychological phenomena | D011579 |
mental disorders | D001523 |
musculoskeletal and neural physiological phenomena | D055687 |
Trade Name
FDA
EMA
Combinations
Citanest, Oraqix (generic drugs available since 2003-08-18, discontinued: Emla)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Epinephrine bitartrate
+
Prilocaine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CITANEST FORTE DENTAL | Dentsply Pharmaceutical | N-021383 RX | 1982-01-01 | 1 products, RLD, RS |
Show 1 discontinued
Lidocaine
+
Prilocaine
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ORAQIX | Dentsply Pharmaceutical | N-021451 RX | 2003-12-19 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
citanest plain | ANDA | 2021-11-10 |
lidocaine and prilocaine | ANDA | 2023-04-17 |
oraqix | New Drug Application | 2018-11-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
137 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pain | D010146 | EFO_0003843 | R52 | 2 | 3 | 5 | 3 | 6 | 18 |
Postoperative pain | D010149 | G89.18 | 1 | — | — | 3 | 2 | 6 | |
Healthy volunteers/patients | — | 2 | — | — | 1 | 3 | 6 | ||
Spinal anesthesia | D000775 | — | — | — | 1 | 3 | 4 | ||
Contraception | D003267 | — | — | 2 | 2 | — | 4 | ||
Actinic keratosis | D055623 | L57.0 | 3 | — | — | 1 | — | 4 | |
Brachial plexus block | D065527 | — | — | — | 3 | — | 3 | ||
Anesthesia | D000758 | — | — | — | 1 | 2 | 3 | ||
Nerve block | D009407 | — | — | — | 2 | — | 2 | ||
Hemorrhoids | D006484 | EFO_0009552 | K64 | — | — | 1 | 1 | — | 2 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Local anesthesia | D000772 | — | 2 | 1 | — | 2 | 4 | ||
Analgesia | D000698 | — | — | 1 | — | 2 | 3 | ||
Hypotension | D007022 | EFO_0005251 | I95 | — | — | 1 | — | 1 | 2 |
Premature ejaculation | D061686 | HP_0012876 | F52.4 | — | 2 | 1 | — | — | 2 |
Hemorrhoidectomy | D061865 | — | 1 | 1 | — | — | 1 | ||
Bone marrow diseases | D001855 | — | — | 1 | — | — | 1 | ||
Procedural pain | D000073818 | — | — | 1 | — | — | 1 | ||
Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | 1 | — | — | 1 | |
Postpartum period | D049590 | — | — | 1 | — | — | 1 | ||
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Wounds and injuries | D014947 | T14.8 | — | 1 | — | — | — | 1 | |
Postherpetic neuralgia | D051474 | — | 1 | — | — | — | 1 | ||
Neoplasms | D009369 | C80 | — | 1 | — | — | — | 1 | |
Thalassemia | D013789 | EFO_1001996 | D56 | — | 1 | — | — | — | 1 |
Memory disorders | D008569 | 1 | 1 | — | — | — | 1 | ||
Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 1 | |
Cataract | D002386 | EFO_0001059 | H26.9 | 1 | 1 | — | — | — | 1 |
Glaucoma | D005901 | EFO_0000516 | H40 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Ambulatory surgical procedures | D000556 | — | — | — | — | 2 | 2 | ||
Pruritus | D011537 | HP_0000989 | L29 | — | — | — | — | 2 | 2 |
Musculoskeletal diseases | D009140 | — | — | — | — | 2 | 2 | ||
Laparoscopic cholecystectomy | D017081 | — | — | — | — | 1 | 1 | ||
Cholelithiasis | D002769 | EFO_0004799 | K80 | — | — | — | — | 1 | 1 |
Inguinal hernia | D006552 | HP_0000023 | K40 | — | — | — | — | 1 | 1 |
Umbilical hernia | D006554 | K42 | — | — | — | — | 1 | 1 | |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
Arthritis | D001168 | EFO_0005856 | M05-M14 | — | — | — | — | 1 | 1 |
Show 24 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | PRILOCAINE |
INN | prilocaine |
Description | Prilocaine is an amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic. It has a role as a local anaesthetic and an anticonvulsant. It is an amino acid amide and a monocarboxylic acid amide. |
Classification | Small molecule |
Drug class | local anesthetics |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCCNC(C)C(=O)Nc1ccccc1C |
Identifiers
PDB | — |
CAS-ID | 721-50-6 |
RxCUI | 8686 |
ChEMBL ID | CHEMBL1194 |
ChEBI ID | 8404 |
PubChem CID | 4906 |
DrugBank | DB00750 |
UNII ID | 046O35D44R (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,606 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,341 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more